Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry News Roundup

This article was originally published in The Tan Sheet

Executive Summary

MediNatura buys Heel Group USA; FDA refuses to file Rock Creek Pharmaceuticals NDI notification; FTC bans businessman from weight-loss industry; AHPA recommends cannabis quality-control regulations; new leadership team at NBTY; FDA cites supplement inflammation claims; and Green Cures signs marketing partners.

You may also be interested in...



OTC Homeopathy Group Revises Label Disclaimers In Light Of FTC Scrutiny

American Association of Homeopathic Pharmacists says its new recommended disclaimer for product labels – saying claims are not based on accepted medical evidence – is supported by research showing the language is clear to consumers. 

OTC Homeopathy Group Revises Label Disclaimers In Light Of FTC Scrutiny

American Association of Homeopathic Pharmacists says its new recommended disclaimer for product labels – saying claims are not based on accepted medical evidence – is supported by research showing the language is clear to consumers. 

Carlyle Group Gives NBTY Helm To Former Coca-Cola Executive Cahillane

Steven Cahillane, who left his post as president of Coca-Cola Co.’s Americas division in 2013, is moving to NBTY to replace Jeffrey Nagel after the supplement manufacturer and retailer reported flat sales for its most recent earnings period and after net income dropped nearly 12% during the firm’s previous fiscal year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS107151

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel